Cardiac Dysfunction Due to Cancer Therapy: Finding New Directions

Circ Res. 2016 Oct 28;119(10):1055-1056. doi: 10.1161/CIRCRESAHA.116.309902.

Authors

Sergey Ryzhov¹, Sanjeev Francis¹, Douglas B Sawyer²

Affiliations

¹ From the Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough (S.R., D.B.S.); and the Department of Cardiac Services, Maine Medical Center, Portland (S.F., D.B.S.).
² From the Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough (S.R., D.B.S.); and the Department of Cardiac Services, Maine Medical Center, Portland (S.F., D.B.S.). DSawyer@mmc.org.

PMID: 27789582
DOI: 10.1161/CIRCRESAHA.116.309902

No abstract available

Keywords: Editorials; anthracyclines; attention; cardiotoxicity; genetic testing; immune system.

Publication types

Editorial
Comment

MeSH terms

Anthracyclines*
Antineoplastic Agents
Cardiotoxicity*
Humans
Neoplasms

Substances

Anthracyclines
Antineoplastic Agents